South Alabama Medical Science Foundation v. Gnosis S.P.A.
808 F.3d 823
Fed. Cir.2015Background
- SAMSF owns three patents ('915, '381, '778) claiming methods and compositions using substantially chirally pure L-5-MTHF (a reduced folate) plus an "essential nutrient preparation" (a vitamin other than ascorbic acid) to treat folate-deficiency-related conditions (e.g., elevated homocysteine, vascular and pregnancy-related conditions).
- Gnosis petitioned for inter partes review of specified claims; the PTAB found those claims obvious over Serfontein (EP '005) and Marazza (U.S. '611 patent) and invalid under 35 U.S.C. § 103.
- Serfontein teaches treating elevated homocysteine with folate or an active folate metabolite plus vitamins B6/B12; Marazza identifies L-5-MTHF as a natural folate metabolite and a promising option for folate deficiency.
- SAMSF argued the prior art taught away from using L-5-MTHF (stability, metabolism, possible homocysteine increase) and relied on objective indicia (commercial success, industry praise, licensing, first-to-recognize a subgroup) to rebut obviousness.
- The PTAB found a motivation to combine Serfontein and Marazza and held objective indicia lacked an adequate nexus to the claimed limitations; it discounted licensing evidence for lack of nexus to products.
- The Federal Circuit majority affirmed the PTAB’s obviousness finding (substantial evidence supports motivation to combine and failure of secondary considerations to overcome obviousness), but found the PTAB erred in its treatment of licensing evidence (harmless error because licensing would not overcome prior-art evidence). Judge Newman dissented, arguing the combination did not establish a motivation with reasonable expectation of success and that secondary considerations supported nonobviousness.
Issues
| Issue | Plaintiff's Argument (SAMSF) | Defendant's Argument (Gnosis/PTAB) | Held |
|---|---|---|---|
| Obviousness of claims over Serfontein + Marazza | Prior art teaches away (instability, poor polyglutamation, possible homocysteine increase); no motivation tocombine with reasonable expectation of success | Serfontein invites use of a "suitable active metabolite" and Marazza points to L-5-MTHF; a person of ordinary skill would be motivated to combine | Affirmed obviousness—substantial evidence supports motivation to combine and conclusion of obviousness |
| Evidentiary weight of objective indicia (commercial success, praise) | Commercial success and industry praise for Pamlab products (Metanx, etc.) show nonobviousness | Successful products are specific formulations not commensurate in scope with claims; praise directed to known L-5-MTHF ingredient, not novel claim features | PTAB correctly found insufficient nexus; objective indicia do not overcome obviousness |
| Nexus for licensing evidence | Licenses to Merck and sublicenses to Pamlab show recognition of claimed invention and support nonobviousness | PTAB required link between licensed products and claimed invention; argued lack of nexus to products | Court: PTAB erred in demanding product-level nexus for licensing, but error was harmless—licensing would not change ultimate obviousness result |
| Inventors’ discovery of a subpopulation needing L-5-MTHF | Inventors first recognized subset with folic-acid processing problems—supports nonobviousness | Claims are not limited to that subset; administration of L-5-MTHF generally was known | PTAB’s treatment harmless—discovery, even if novel, does not show patentability here given claim scope |
Key Cases Cited
- Medichem, S.A. v. Rolabo, S.L., 437 F.3d 1157 (Fed. Cir.) (obviousness involves motivation to combine and secondary considerations)
- Graham v. John Deere Co., 383 U.S. 1 (1966) (framework for obviousness analysis)
- In re Mouttet, 686 F.3d 1322 (Fed. Cir.) (standard of review: factual findings for substantial evidence, obviousness de novo)
- Rambus Inc. v. Rea, 731 F.3d 1248 (Fed. Cir.) (patentee need not show commercial success for every embodiment; nexus requirements)
- In re Huai-Hung Kao, 639 F.3d 1057 (Fed. Cir.) (commercial success must be reasonably commensurate in scope with the claims)
- In re GPAC Inc., 57 F.3d 1573 (Fed. Cir.) (licensing can show nexus when it arises from recognition of claimed subject matter)
- Leo Pharm. Prods., Ltd. v. Rea, 726 F.3d 1346 (Fed. Cir.) (discovery of a previously unrecognized problem can affect motivation-to-combine analysis)
- Gnosis S.p.A. v. Merck & Cie, 808 F.3d 829 (Fed. Cir.) (companion decision addressing similar obviousness issues)